EGRX - EGRX INVESTOR ALERT: Hagens Berman National Trial Attorneys Encourages Eagle Pharmaceuticals (EGRX) Investors with Substantial Losses to Contact Firm Securities Fraud Lawsuit Filed After Company Admits Accounting Problems | Benzinga

SAN FRANCISCO, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investors who suffered substantial losses to submit your losses now.

Class Period: Aug. 8, 2023 – Nov. 28, 2023
Lead Plaintiff Deadline: Feb. 9, 2024
Visit: www.hbsslaw.com/investor-fraud/EGRX
Contact An Attorney Now: EGRX@hbsslaw.com
                                                    844-916-0895

Eagle Pharmaceuticals, Inc. (EGRX) Securities Fraud Class Action:

On Dec. 15, 2023, Eagle Pharmaceuticals (EGRX) revealed that the scope of its admitted improper accounting and anticipated restatement has now expanded to include 2Q 2023. What's more, the company disclosed that its delivery of inaccurate 2Q 2023 results has triggered an event of default under its $100 million revolving line of credit agreement, presenting the risk lenders could call outstanding amounts due or foreclose on the company's assets.

Eagle's recent disclosure follows the filing of an investor class action against Eagle Pharmaceuticals and its executives challenging the company's admitted improper accounting for 3Q 2023.

The securities class action lawsuit alleges that Defendants misrepresented and failed to disclose that: (i) Eagle Pharmaceuticals was experiencing slower than anticipated pull-though from a wholesale customer predominantly due to expiry of ...

EGRX) Investors with Substantial Losses to Contact Firm, Securities Fraud Lawsuit Filed After Company Admits Accounting Problems>Full story available on Benzinga.com